Petros Grivas
@pgrivasmdphd
Oncologist, Professor, clinical/translational research, Genitourinary Cancers, bladder, prostate, testis, Univ of Washington, Fred Hutch; views are mine
ID: 3379037548
https://www.fredhutch.org/en/faculty-lab-directory/grivas-petros.html 16-07-2015 16:21:53
21,21K Tweet
17,17K Takipçi
12,12K Takip Edilen
Thomas Flaig Jean Hoffman-Censits Elizabeth Plimack MD Ravindran Kanesvaran Vadim Koshkin MD Matt Milowsky Yuji Miura Jonathan Rosenberg MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Javier Puente Sarah P. Psutka MD MS Daniel Petrylak Howard Gurney Alessandro Volpe 7/Other 2L options(depending on prior tx): ✔️Erda for FGFR3 alterations ✔️EV monotx Taxane if no access to☝️ ✔️Nivo or avelumab if no access to pembro + ICI naïve ✔️T-DXd for HER2 3+ IHC (gastric Ca scoring) ✔️Sacituzumab govitecan (FDA indication withdrawn) Peter Black Yohann Loriot